Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
- Author
- KAWAOKA, Tomokazu1 ; AIKATA, Hiroshi1 ; HIRAMATSU, Akira1 ; WAKI, Koji1 ; TAKAHASHI, Shoichi1 ; CHAYAMA, Kazuaki1 ; MURAKAMI, Eisuke1 ; NAKAHARA, Takashi1 ; NAESHIRO, Noriaki1 ; TANAKA, Mio1 ; HONDA, Yoji1 ; MIYAKI, Daisuke1 ; NAGAOKI, Yuko1 ; TAKAKI, Shintaro1
[1] Department of Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University, Hiroshima, Japan - Source
Oncology. 2012, Vol 83, Num 4, pp 192-200, 9 p ; ref : 26 ref
- ISSN
- 0030-2414
- Scientific domain
- Medical oncology
- Publisher
- Karger, Basel
- Publication country
- Switzerland
- Document type
- Article
- Language
- English
- Author keyword
- Child-Pugh score Hepatocellular carcinoma Sorafenib mRECIST α-Fetoprotein
- Keyword (fr)
- Antiangiogénique Anticancéreux Antigène associé tumeur Antigène oncofoetal Cancer du foie Cancérologie Carcinome hépatocellulaire Enfant Foetoprotéine α Homme Marqueur tumoral Pronostic Sorafénib Stade avancé Traitement Score Cancer Inhibiteur de la tyrosine kinase Inhibiteur enzyme Inhibiteur multikinase Pathologie de l'appareil digestif Pathologie du foie Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Tumor associated antigen Oncofetal antigen Liver cancer Cancerology Hepatocellular carcinoma Child α-Fetoprotein Human Tumoral marker Prognosis Sorafenib Advanced stage Treatment Score Cancer Tyrosine kinase inhibitor Enzyme inhibitor Multikinase inhibitor Digestive diseases Hepatic disease Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Antígeno asociado tumor Antígeno oncofetal Cáncer del hígado Cancerología Carcinoma hepatocelular Niño Fetoproteina α Hombre Marcador tumoral Pronóstico Sorafenib Estadio avanzado Tratamiento Cáncer Inhibidor tyrosine kinase Inhibidor enzima inhibidor multicinasa Aparato digestivo patología Hígado patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26318597
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1159/000341347 
https://dx.doi.org/10.1159/000341347
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000341347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"192\";s:8:\"\u0000*\u0000epage\";s:3:\"200\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KAWAOKA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tomokazu\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:15:\"AIKATA, Hiroshi\";i:1;s:16:\"HIRAMATSU, Akira\";i:2;s:10:\"WAKI, Koji\";i:3;s:18:\"TAKAHASHI, Shoichi\";i:4;s:16:\"CHAYAMA, Kazuaki\";i:5;s:16:\"MURAKAMI, Eisuke\";i:6;s:17:\"NAKAHARA, Takashi\";i:7;s:17:\"NAESHIRO, Noriaki\";i:8;s:11:\"TANAKA, Mio\";i:9;s:11:\"HONDA, Yoji\";i:10;s:15:\"MIYAKI, Daisuke\";i:11;s:13:\"NAGAOKI, Yuko\";i:12;s:16:\"TAKAKI, Shintaro\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000341347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"192\";s:8:\"\u0000*\u0000epage\";s:3:\"200\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KAWAOKA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tomokazu\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:15:\"AIKATA, Hiroshi\";i:1;s:16:\"HIRAMATSU, Akira\";i:2;s:10:\"WAKI, Koji\";i:3;s:18:\"TAKAHASHI, Shoichi\";i:4;s:16:\"CHAYAMA, Kazuaki\";i:5;s:16:\"MURAKAMI, Eisuke\";i:6;s:17:\"NAKAHARA, Takashi\";i:7;s:17:\"NAESHIRO, Noriaki\";i:8;s:11:\"TANAKA, Mio\";i:9;s:11:\"HONDA, Yoji\";i:10;s:15:\"MIYAKI, Daisuke\";i:11;s:13:\"NAGAOKI, Yuko\";i:12;s:16:\"TAKAKI, Shintaro\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000341347\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000341347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"192\";s:8:\"\u0000*\u0000epage\";s:3:\"200\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KAWAOKA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tomokazu\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:15:\"AIKATA, Hiroshi\";i:1;s:16:\"HIRAMATSU, Akira\";i:2;s:10:\"WAKI, Koji\";i:3;s:18:\"TAKAHASHI, Shoichi\";i:4;s:16:\"CHAYAMA, Kazuaki\";i:5;s:16:\"MURAKAMI, Eisuke\";i:6;s:17:\"NAKAHARA, Takashi\";i:7;s:17:\"NAESHIRO, Noriaki\";i:8;s:11:\"TANAKA, Mio\";i:9;s:11:\"HONDA, Yoji\";i:10;s:15:\"MIYAKI, Daisuke\";i:11;s:13:\"NAGAOKI, Yuko\";i:12;s:16:\"TAKAKI, Shintaro\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000341347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"192\";s:8:\"\u0000*\u0000epage\";s:3:\"200\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KAWAOKA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tomokazu\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:15:\"AIKATA, Hiroshi\";i:1;s:16:\"HIRAMATSU, Akira\";i:2;s:10:\"WAKI, Koji\";i:3;s:18:\"TAKAHASHI, Shoichi\";i:4;s:16:\"CHAYAMA, Kazuaki\";i:5;s:16:\"MURAKAMI, Eisuke\";i:6;s:17:\"NAKAHARA, Takashi\";i:7;s:17:\"NAESHIRO, Noriaki\";i:8;s:11:\"TANAKA, Mio\";i:9;s:11:\"HONDA, Yoji\";i:10;s:15:\"MIYAKI, Daisuke\";i:11;s:13:\"NAGAOKI, Yuko\";i:12;s:16:\"TAKAKI, Shintaro\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000341347\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"192\";s:8:\"\u0000*\u0000epage\";s:3:\"200\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KAWAOKA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Tomokazu\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:15:\"AIKATA, Hiroshi\";i:1;s:16:\"HIRAMATSU, Akira\";i:2;s:10:\"WAKI, Koji\";i:3;s:18:\"TAKAHASHI, Shoichi\";i:4;s:16:\"CHAYAMA, Kazuaki\";i:5;s:16:\"MURAKAMI, Eisuke\";i:6;s:17:\"NAKAHARA, Takashi\";i:7;s:17:\"NAESHIRO, Noriaki\";i:8;s:11:\"TANAKA, Mio\";i:9;s:11:\"HONDA, Yoji\";i:10;s:15:\"MIYAKI, Daisuke\";i:11;s:13:\"NAGAOKI, Yuko\";i:12;s:16:\"TAKAKI, Shintaro\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:155:\"Evaluation of the mRECIST and \u03b1-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
